Cingulate Inc.
CINGHealthcare|Biotechnology|US
$4.26
+0.02 (+0.47%)
DCF Value
$0.05
Tangible Book / Share
$4.32
Cash / Share
$5.23
About
Cingulate Inc. is a biopharmaceutical enterprise currently in its clinical development phase, dedicated to devising therapeutic options for attention-deficit/hyperactivity disorder (ADHD). Leading its pipeline for ADHD are two drug candidates: CTx-1301 (dexmethylphenidate), which is currently progressing through Phase 3 clinical trials, and CTx-1302 (dextroamphetamine). The company is also engaged in the advancement of CTx-2103, a candidate intended for the management of anxiety disorders. Founded in 2012, Cingulate Inc. maintains its corporate headquarters in Kansas City, Kansas.
Stock Price
+15.8%(1Y)
1M
-12.7%
3M
-20.2%
6M
-19.2%
YTD
-1.8%
1Y
+17.4%
3Y
-95.1%
5Y
-99.6%
Pipeline Summary
6 total trials3
Phase 1
1
Phase 2
3
Phase 3
0
Phase 4
Completed: 5Suspended: 1
Key Facts
Market Cap$61.9M
Employees14 (+8% YoY)
CEOShane J. Schaffer
IPO DateDec 8, 2021
Beta-0.89
52-Week Range$3.16 – $11.89
Avg Volume149,899
ExchangeNASDAQ
Websitecingulate.com
Ownership
Float83.5%
Shares Outstanding14.5M
Recent Insider Trades
Silva Raul R.AWARD
Sep 30, 20264,293 shares @ $4.95
Schaffer Shane J.AWARD
Jul 16, 2026197,650 shares @ $4.43
Schaffer Shane J.AWARD
Jul 16, 202697,350 shares @ $4.43
Downey Bryan WadeAWARD
Jul 16, 202667,000 shares @ $4.43
Downey Bryan WadeAWARD
Jul 16, 202633,000 shares @ $4.43
Peers
Recent News
Shane Schaffer, Cingulate Chairman & CEO to Present “SMART Launch” Approach at Indegene Digital Summit: Rethinking Commercialization for Emerging Pharma
Sep 17, 2026 · globenewswire.com
Cingulate Inc. Reports Second Quarter 2026 Financial Results and Provides Update on CTx-1301 CMC Progress Towards NDA Resubmission and Commercial Readiness
Aug 13, 2026 · globenewswire.com
Cingulate Publishes Peer-Reviewed Data Demonstrating CTx-1301's Differentiated Pharmacokinetic Profile
Aug 11, 2026 · globenewswire.com
Data last updated: Nov 9, 2026, 04:02 AM